

ASX ANNOUNCEMENT

CHANGE OF REGISTRY ADDRESS

SYDNEY, Tuesday 30 June 2015: Cellmid Limited (ASX:CDY) would like to advise shareholders that the address for Boardroom Pty Limited (**BoardRoom**), the Company's Share Registry, has now changed to:

Level 12
225 George Street
Sydney NSW 2000

All other contact details remain unchanged. For clarity these are listed below:

Postal address:

GPO Box 3993
Sydney NSW 2001

Telephone numbers:

Within Australia: 1300 737 760
Outside of Australia: +61 2 9290 9600

Security holders, member organisations and other parties must now lodge documentation at this new address.

End
Contact:
Maria Halasz CEO
T +612 9221 6830

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company with lead drug candidates in oncology and nephropathy. The Company is developing innovative novel therapies and diagnostic tests for a number of cancer indications and kidney diseases. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see www.cellmid.com.au.

Advangen Limited

In 2013 Cellmid acquired Advangen Inc. (Japan), the owner of a range of FGF5 hair growth technologies and products. Since then, Cellmid's FGF5 inhibitor assets have been consolidated in its wholly owned subsidiary, Advangen Limited. Cellmid, under Advangen Limited, has continued innovation and product development in addition to actively building distribution in Australia, China, Japan and other major markets. Since the acquisition of Advangen Inc., Advangen Limited filed a number of new patent applications covering several hair growth agents including midkine, pleiotrophin and a group of novel FGF5 inhibitors.

Investment in life sciences companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.